All In Biotech

Drug Trial Radar · NCT00405067

The Safety & Efficacy of Combination BMS-201038 (AEGR-733) & Ezetimibe vs. Monotherapy in Moderate Hypercholesterolemia

A Randomized, Double-Blind, Active Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of the Combination BMS-201038 (AEGR-733) and Ezetimibe vs. Monotherapy in Subjects With Moderate Hypercholesterolemia

Last checked: Nov 20, 2026Latest source record: Mar 4, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

60

Actual

Start

May 2006

Primary completion

Jan 2007

Study completion Jan 2007

Sponsor

Lead sponsor
Aegerion Pharmaceuticals, Inc.Industry
Sponsor type
Industry
First posted
Nov 29, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main objectives of this study are to evaluate the efficacy and safety of combination therapy BMS-201038 (AEGR-733) plus ezetimibe vs. each agent given alone on LDL cholesterol and other lipoproteins over 12 weeks of therapy.

Conditions

  • Hypercholesterolemia

Interventions

  • BMS-201038 (AEGR-733)Drug

  • EzetimibeDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent Change in LDL-C at 12 Weeks Therapy Compared to Baseline Between TreatmentsTime frame: Baseline and 12 weeks of treatment

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Pharmanet, Inc

    Princeton, New Jersey

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.